Browse

Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization

DC Field Value Language
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorKim, Jin Won-
dc.contributor.authorKim, Jin-Soo-
dc.contributor.authorKim, Min A.-
dc.contributor.authorJordan, Bruce-
dc.contributor.authorPickl, Marlene-
dc.contributor.authorHan, Sae-Won-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorLee, Hyuk Joon-
dc.contributor.authorKim, Tae-You-
dc.contributor.authorKim, Woo Ho-
dc.contributor.authorYang, Han-Kwang-
dc.contributor.authorBang, Yung-Jue-
dc.date.accessioned2021-01-31T11:08:46Z-
dc.date.available2021-01-31T11:08:46Z-
dc.date.issued2011-06-
dc.identifier.citationDiagnostic Molecular Pathology, Vol.20 No.2, pp.94-100-
dc.identifier.issn1052-9551-
dc.identifier.other119684-
dc.identifier.urihttps://hdl.handle.net/10371/173057-
dc.description.abstractDespite recent advances in chemotherapy, the prognosis for patients with advanced gastric cancer (GC) or gastroesophageal junction cancer remains poor. Human epidermal growth factor receptor 2 (HER2) is a novel target for biologic therapy in metastatic GC. We analyzed the association between HER2 overexpression and the clinicopathologic characteristics of advanced GC. Formalin-fixed, paraffin-embedded tumor samples were collected from patients with stage III or to IV (M-0) GC who subsequently underwent curative surgery followed by adjuvant chemotherapy with 5-fluorouracil and cisplatin. All the samples were analyzed for HER2 status by immunohistochemistry (IHC) and fluorescence in situ hybridization. Of 142 samples analyzed, 7.1% scored IHC 2+ and 8.6% scored IHC 3+, whereas 9.3% were HER2-amplified. Of HER2-amplified cases, 76.9% (10/13) scored IHC 3+, showing the correlation between HER2 amplification and overexpression (P = 0.01). HER2 IHC 3+ cases were more common in the intestinal-type tumors compared with diffuse-type tumors (16.7% vs. 5.1%, respectively; P = 0.049), and a nonsignificant trend was observed using fluorescence in situ hybridization (14.3% vs. 9.2%, respectively; P = 0.399). HER2 gene amplification was more frequent in stage IV (M-0) than stage III disease (15.4% vs. 4.0%, respectively; P = 0.037). Interestingly, HER2-amplified disease was more common than nonamplified disease in patients with nodal stage 3 tumors (76.9% vs. 38.6%, respectively; P = 0.009); a similar pattern was observed using IHC. HER2 overexpression correlated with nodal stage, and a lymph node ratio greater than 0.5 was more common in HER2-amplified tumors than HER2-nonamplified tumors (69.2% vs. 43.3%, respectively; P = 0.086). These findings suggest that further investigations of adjuvant therapy with HER2-targeted therapy for advanced GC are warranted.-
dc.subjectHER2-
dc.subjectimmunohistochemistry-
dc.subjectfluorescence in situ hybridization-
dc.subjectgastric cancer-
dc.titleClinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization-
dc.typeArticle-
dc.contributor.AlternativeAuthor임석아-
dc.identifier.doi10.1097/PDM.0b013e3181fc02b7-
dc.citation.journaltitleDiagnostic Molecular Pathology-
dc.identifier.scopusid2-s2.0-79958066203-
dc.citation.endpage100-
dc.citation.number2-
dc.citation.startpage94-
dc.citation.volume20-
dc.identifier.urlhttps://journals.lww.com/molecularpathology/Fulltext/2011/06000/Clinicopathologic_Characteristics_of_Patients_With.5.aspx-
dc.identifier.rimsid119684-
dc.identifier.sci000290662100005-
dc.contributor.affiliatedAuthorIm, Seock-Ah-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse